371 enterococcus faecalis tx0104 hm 201 640 454 583  (ATCC)

Journal: The Journal of antibiotics

Article Title: Screening for potent and selective anticlostridial leads among FDA-approved drugs

doi: 10.1038/s41429-020-0288-3

Figure Lengend Snippet: MICs (μg/mL) of the active compounds against human normal gut flora

Article Snippet: The MIC of nithiamide against most of the inhibited microbiota strains was much higher than its MIC 50 against C. difficile ( ). table ft1 table-wrap mode="anchored" t5 Table 4: caption a7 Bacterial Strain Strain ID Nitroimidazole Imidazole antifungals Ronidazole Dimetridazole Ornidazole Tinidazole Miconazole Econazole Tioconazole Butoconazole Clotrimazole Lactobacillus casei ATCC-334 >640 >907 >583 >518 308 335 330 311 371 Lactobacillus acidophilus ATCC-314 640 >907 >583 >518 308 335 >330 >311 371 Bifidobacterium bifidum ATCC-11863 ≤5 ≤7 ≤5 32 10 21 21 19 23 Bifidobacterium breve ATCC-15700 ≤5 227 146 518 38 42 41 39 46 Bifidobacterium longum HM-845 ≤5 ≤7 36 16 38 42 41 5 46 Bifidobacterium breve HM-856 >640 >907 >583 >518 38 42 >330 10 46 Bacteroides fragilis HM-711 ≤5 28 ≤5 ≤4 38 42 5 10 46 Bacteroides fragilis HM-709 ≤5 28 ≤5 ≤4 19 21 ≤3 10 46 Lactobacillus crispatus HM-371 640 907 >583 >518 308 335 >330 >311 371 Lactobacillus gasseri HM-407 320 907 >583 >518 308 335 >330 >311 371 Escherichia coli ATCC-35150 640 113 >583 >518 >308 >335 >330 78 >371 Escherichia coli 1411 640 113 >583 >518 >308 >335 >330 78 >371 Enterococcus faecalis -- TX0104 HM-201 640 454 >583 >518 38 42 >330 19 >371 Enterococcus faecalis -- TX1322 HM-202 >640 907 >583 >518 19 42 >330 19 46 Open in a separate window Strain Strain ID Salicylanilides Miscellaneous Vancomycin Metronidazole Closantel Oxyclozanide Niclosamide Nitazoxanide Dichlorophene Triclabendazole Nithiamide Lactobacillus casei ATCC-334 193 80 196 >417 >476 >356 >684 >88 >748 Lactobacillus acidophilus ATCC-314 97 40 >391 >417 >476 >356 >684 0.7 >47 Bifidobacterium bifidum ATCC-11863 ≤1.5 40 ≤3 ≤3 30 11 ≤5 0.7 5.8 Bifidobacterium breve ATCC-15700 ≤1.5 10 ≤3 ≤3 30 22 ≤5 2.8 47 Bifidobacterium longum HM-845 ≤1.5 ≤2.5 ≤3 52 30 5.5 ≤5 0.3 23 Bifidobacterium breve HM-856 3 40 ≤3 26 30 22 ≤5 0.3 >748 Bacteroides fragilis HM-711 3 5 6 26 30 44 43 88 ≤5.8 Bacteroides fragilis HM-709 3 5 ≤3 26 30 22 11 44 ≤5.8 Lactobacillus crispatus HM-371 12 >319 49 417 476 >356 342 1.4 >748 Lactobacillus gasseri HM-407 12 >319 49 417 476 >356 342 1.4 >748 Escherichia coli ATCC-35150 >193 >319 >391 >417 >476 >356 >684 ND ND Escherichia coli 1411 193 >319 >391 >417 >476 >356 >684 ND ND Enterococcus faecalis -- TX0104 HM-201 24 >319 >391 26 59 22 11 >88 ND Enterococcus faecalis -- TX1322 HM-202 24 >319 >391 26 59 11 11 0.7 ND Open in a separate window ND= Not detected MICs (μg/mL) of the active compounds against human normal gut flora To summarize, we screened two libraries consisting of FDA-approved drugs and clinical molecules against C. difficile in order to identify potent and selective inhibitors.

Techniques: